9 results match your criteria: "University of Washington and Fred Hutch Cancer Center[Affiliation]"
Phys Med
September 2025
Department of Radiation Oncology, University of Washington and Fred Hutch Cancer Center, 1959 NE Pacific St., Seattle, WA 98195, USA.
Purpose: Evaluation of treatment plan quality is a critical element of training for radiotherapy professionals. With the increased adoption of intensity modulated radiotherapy internationally, this training is crucial to address patient care inequity. We aim to evaluate learning outcomes from a 14-session remote training course targeting critical elements of plan quality with advanced modalities.
View Article and Find Full Text PDFEur Urol
August 2025
Department of Medicine, Division of Hematology Oncology, University of Washington and Fred Hutch Cancer Center, Seattle, WA, USA. Electronic address:
Muscle-invasive bladder cancer (MIBC) with histologic subtypes represents a clinical challenge because of poor responses to conventional therapies and under-representation in clinical trials. This single-center phase 2 trial evaluated the combination of neoadjuvant pembrolizumab and accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (aMVAC) chemotherapy in patients with pure or predominant nonurothelial histologies. Seventeen patients were enrolled, with squamous differentiation being the most common variant.
View Article and Find Full Text PDFKidney Int
July 2025
Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Electronic address:
Patients with plasma cell dyscrasias, including multiple myeloma, AL amyloidosis, and monoclonal gammopathy of renal significance, face a high burden of end-stage kidney disease, which limits survival and quality of life. Although kidney transplantation offers potential benefits, it remains underused because of the high risk of recurrence and historically poor outcomes. A multidisciplinary panel of transplant nephrologists, hematologists/oncologists, and pathologists convened to evaluate contemporary evidence and evolving strategies in kidney transplant for plasma cell dyscrasias and end-stage kidney disease.
View Article and Find Full Text PDFBrachytherapy
August 2025
Department of Radiation Oncology, Odette Cancer Centre - Sunnybrook Health Sciences Centre, University of Toronto, Canada.
Brachytherapy is an essential skill in the practice of radiation oncology and is an important component of high-quality, full-service radiation oncology departments. With rapidly changing technology, the role of brachytherapy is constantly evolving, but it remains critically important for optimal patient care in several disease sites. As a procedural aspect of radiation oncology practice, brachytherapy requires a fundamentally different and more focused training approach, with specific training objectives, a unique knowledge base, and specialized training environment.
View Article and Find Full Text PDFJ Virol
July 2025
Basic Sciences and Computational Biology Divisions, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Vaccines and monoclonal antibodies targeting the respiratory syncytial virus (RSV) fusion protein (F) have recently begun to be widely used to protect infants and high-risk adults. Some other viral proteins evolve to erode polyclonal antibody neutralization and escape individual monoclonal antibodies. However, the impact of RSV F evolution on antibody neutralization is not yet thoroughly understood.
View Article and Find Full Text PDFAm J Transplant
August 2025
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Maryland, USA.
bioRxiv
March 2025
Basic Sciences and Computational Biology Divisions, Fred Hutchinson Cancer Center, Seattle, WA 98109.
Vaccines and monoclonal antibodies targeting the respiratory syncytial virus (RSV) fusion protein (F) have recently begun to be widely used to protect infants and high-risk adults. Some other viral proteins evolve to erode polyclonal antibody neutralization and escape individual monoclonal antibodies. However, little is known about how RSV F evolution affects antibodies.
View Article and Find Full Text PDFAm J Transplant
August 2025
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Belatacept is a selective T cell costimulation blocker used in maintenance immunosuppression for kidney transplant recipients (KTRs), but evidence on cancer risk and other outcomes is limited. This retrospective cohort study used linked US transplant and cancer registry data on KTRs treated with belatacept (N = 1514) or tacrolimus (N = 7570) as initial maintenance therapy. We used multivariable Cox regression models to compare the incidence of invasive cancer, cutaneous squamous cell carcinoma, posttransplant lymphoproliferative disorder (PTLD), death, and graft failure/retransplantation (GF/RT) between belatacept and tacrolimus users.
View Article and Find Full Text PDFInt J Radiat Oncol Biol Phys
May 2025
Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio. Electronic address:
Purpose: Meningiomas are the most common primary intracranial tumor. Somatostatin receptor 2 is almost universally expressed in meningioma tissue. For patients who require adjuvant radiation, somatostatin receptor based (68)Ga-DOTATATE positron emission tomography (PET) imaging can detect additional or residual disease not discernible on magnetic resonance imaging.
View Article and Find Full Text PDF